Skip to main content
eScholarship
Open Access Publications from the University of California

Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies.

  • Author(s): Goodman, Aaron M
  • Kato, Shumei
  • Cohen, Philip R
  • Boichard, Amélie
  • Frampton, Garrett
  • Miller, Vincent
  • Stephens, Philip J
  • Daniels, Gregory A
  • Kurzrock, Razelle
  • et al.

Published Web Location

http://mct.aacrjournals.org/content/16/2/265.long
No data is associated with this publication.
Abstract

Metastatic basal cell cancer (BCC) is an ultra-rare malignancy with no approved therapies beyond Hedgehog inhibitors. We characterized the genomics, tumor mutational burden (TMB), and anti-PD-1 therapy responses in patients with locally advanced or metastatic BCC. Overall, 2,039 diverse cancer samples that had undergone comprehensive genomic profiling (CGP) were reviewed. Eight patients with locally advanced/metastatic BCC were identified (two had two CGP analyses; total, 10 biopsies). Two tumors demonstrated PD-L1 amplification. Seven patients had >1 actionable alteration. The TMB (mutations/mb) (median (range)) was 90 (3-103) for the BCCs versus 4 (1-860) for 1637 cancers other than BCC (P < 0.0001). Median progression-free survival (PFS) for all four patients treated with PD-1 blockade was 10.7 months (range, 3.8 to 17.6+ months); three patients had an objective response. In conclusion, advanced/metastatic BCC often has biological features (high TMB; PD-L1 amplification) predictive of immunotherapy benefit, and patients frequently respond to PD-1 blockade.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Item not freely available? Link broken?
Report a problem accessing this item